共 48 条
- [1] Styczynski J(2018)Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation Infect Dis Ther 7 1-16
- [2] Lachmann R(2018)Cytomegalovirus (CMV) seroprevalence in the adult population of Germany PLoS One 13 e0200267-81
- [3] Stadler LP(2010)Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males Clin Infect Dis 51 e76-1447
- [4] Bate SL(2010)Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004 Clin Infect Dis 50 1439-296
- [5] Dollard SC(2006)The prevalence of human cytomegalovirus seropositivity among blood donors at the Unit of Blood Transfusion Medicine, Hospital Universiti Sains Malaysia Southeast Asian J Trop Med Public Health 37 294-182
- [6] Cannon MJ(1993)Prevalence of cytomegalovirus antibody in Thai-northeastern blood donors Southeast Asian J Trop Med Public Health 24 180-24
- [7] Ahmed SA(2020)Cytomegalovirus disease in patients with hematopoietic stem cell transplantation, experience over 8 years Hematol Transfus Cell Ther 42 18-2016
- [8] Urwijitaroon Y(2015)Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid Leukemia who survived to day 100 after transplantation: the Japan society for hematopoietic cell transplantation transplantation-related complication working group Biol Blood Marrow Transplant 21 2008-1062
- [9] Teawpatanataworn S(2021)Human cytomegalovirus infection: a considerable issue following allogeneic hematopoietic stem cell transplantation Oncol Lett 21 318-e127
- [10] Kitjareontarm A(2007)Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation Bone Marrow Transplant 40 1055-586